Investigations on anti-Aspergillus properties of bacterial products.
OBJECTIVE
To investigate the anti-Aspergillus properties of bacterial products.


RESULTS
In the present study, 12 bacterial strains were screened for antifungal activity against Aspergilli. The culture supernatant and lysates of Pseudomonas aeruginosa, Bacillus cereus, Escherichia coli (BL21, DH5alpha, HB101, XL Blue), Klebsiella pneumoniae, Streptomyces thermonitrificans, Streptococcus pneumoniae, Enterobacter aerogenes, Staphylococcus aureus and Salmonella typhi were examined for antifungal activity in protein concentration ranging from 1000.0 to 7.8 microg ml-1 using microbroth dilution assay. The lysate of Salm. typhi and E. coli BL21 exhibited the maximum activity against Aspergillus fumigatus, Aspergillus flavus and Aspergillus niger. Their in vitro minimum inhibitory concentrations (MICs) were found to be 15.6-31.2 microg ml-1 by microbroth dilution and spore germination inhibition assays. In disc diffusion assay, a concentration of 3.1 microg disc-1 of Salm. typhi lysate showed significant activity against Aspergilli. Escherichia coli BL21 exhibited similar activity at 6.2 microg disc-1. The work on identification of molecule endowed with antimycotic properties is in progress.


CONCLUSIONS
The products of Salm. typhi and E. coli demonstrated significant activity against Aspergillus species.


CONCLUSIONS
This is the first time that E. coli has been reported for anti-Aspergillus activity. It could be an important source of biologically active compounds useful for developing better new antifungal drugs/or probiotics.
Yadav
V
V
Institute of Genomics and Integrative Biology, University Campus, Delhi, India.
Gupta
J
J
Mandhan
R
R
Chhillar
A K
AK
Dabur
R
R
Singh
D D
DD
Sharma
G L
GL
D000935:Antifungal Agents / Q000378:metabolism / Q000494:pharmacology*; D001230:Aspergillus / Q000145:classification / Q000187:drug effects* / Q000502:physiology; D001419:Bacteria / Q000254:growth & development / Q000378:metabolism*; D001426:Bacterial Proteins / Q000378:metabolism / Q000494:pharmacology*; D004926:Escherichia coli / Q000254:growth & development / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D012485:Salmonella typhi / Q000254:growth & development / Q000378:metabolism; D013172:Spores, Fungal / Q000187:drug effects / Q000502:physiology
D000935:Antifungal Agents; D001426:Bacterial Proteins